首页|期刊导航|实用临床医药杂志|载miR-144抑制剂的脂质体杂合红细胞膜纳米药物的构建及初步评价

载miR-144抑制剂的脂质体杂合红细胞膜纳米药物的构建及初步评价OA

Construction and preliminary evaluation of liposomal hybrid erythrocyte membrane nanoparticles carrying miR-144 inhibitor

中文摘要英文摘要

目的 构建载微小RNA-144(miR-144)抑制剂的脂质体杂合红细胞膜(LHRM)纳米递送系统,评价其理化性质、生物相容性、体内循环特性以及体外递送能力.方法 采用低渗裂解法提取红细胞膜,薄膜水化法制备脂质体,并按不同质量比融合构建LHRM纳米颗粒.通过动态光散射(DLS)、Zeta电位及透射电镜(TEM)对纳米颗粒进行表征,并利用DiO、DiI荧光标记实验验证膜融合.通过DiI荧光标记纳米颗粒,并经尾静脉注射至C57BL/6小鼠体内,评价其体内循环情况.以小鼠红白血病细胞(MEL)为体外模型,观察不同配比纳米颗粒的细胞递送能力及细胞毒性,并进一步采用Western blot检测miR-144抑制剂递送后NF-E2相关因子2(Nrf2)蛋白的表达变化.结果 成功构建LHRM纳米载体,其粒径较红细胞膜显著增加,呈规则核壳结构,荧光共定位实验表明膜融合成功.不同配比比较显示,当红细胞膜与脂质体质量比为6∶1时,细胞递送效果最佳.初步测得载miR-144抑制剂的LHRM和脂质体包封率分别为(75.05±5.49)%和(60.23±6.85)%.体内实验中,LHRM组较脂质体显著延缓了血液荧光衰减趋势.MTT结果初步提示LHRM对MEL细胞具有较好的生物相容性,细胞毒性较小;Western blot分析表明,MEL细胞经载miR-144抑制剂的LHRM处理后,可提升细胞的Nrf2蛋白水平.结论 构建的LHRM纳米递送系统具有良好的结构稳定性、生物相容性及递送能力,并在初步体内实验中表现出较脂质体更优的血液荧光衰减趋势.该递送系统的成功构建为成功递送miR-144抑制剂、改善β-地中海贫血细胞的氧化应激提供了生物材料.

Objective To construct a liposomehybrid red blood cell membrane(LHRM)nanode-livery system loaded with microRNA-144(miR-144)inhibitor,and to evaluate its physicochemical properties,biocompatibility,in vivo circulation characteristics,and in vitro delivery capacity.Meth-ods Red blood cell membranes were extracted by hypotonic lysis,liposomes were prepared by thinfilm hydration,and LHRM nanoparticles were fabricated by fusing the two components at various mass ratios.The nanoparticles were characterized by dynamic light scattering(DLS),Zeta potential,and trans-mission electron microscopy(TEM).Membrane fusion was verified by DiO/DiI fluorescence colo-calization assays.The in vivo circulation profile was evaluated by intravenously injecting DiI labeled nanoparticles via the tail vein into C57BL/6 mice.Using mouse erythroleukemia cells(MEL)as an in vitro model,the cellular delivery efficiency and cytotoxicity of nanoparticles with different mass ratios were examined.Furthermore,western blot was performed to detect the expression changes of NF-E2 related factor 2(Nrf2)protein following miR-144 inhibitor delivery.Results The LHRM nanocarriers were successfully constructed,exhibiting a regular core-shell structure with significantly increased particle size compared to red blood cell membranes alone;fluorescence colocalization con-firmed successful membrane fusion.Among the various formulations,the mass ratio of red blood cell membrane to liposome at 6∶1 yielded the optimal cellular delivery efficiency.The preliminary en-capsulation efficiencies of miR-144 inhibitor loaded LHRM and liposomes were(75.05±5.49)%and(60.23±6.85)%,respectively.In in vivo experiments,the LHRM group significantly delayed the blood fluorescence decay trend compared with the liposome group.MTT assay preliminarily indi-cated that LHRM exhibited favorable biocompatibility and low cytotoxicity toward MEL cells.West-ern blot analysis demonstrated that treatment with miR-144 inhibitor loaded LHRM upregulated Nrf2 protein levels in MEL cells.Conclusion The constructed LHRM nanodelivery system possesses fa-vorable structural stability,biocompatibility,and delivery capacity,and demonstrates a superior blood fluorescence decay profile compared to liposomes in preliminary in vivo experiments.The suc-cessful construction of this delivery system provides a biomaterial platform for effective delivery of miR-144 inhibitors and amelioration of oxidative stress in β-thalassemia cells.

崔凌云;卜语优;谷婷;凌玲;奚菊群;梁丽芳;戴华

扬州大学医学部基础医学院·公共卫生学院,江苏扬州,225001||扬州大学医学部第一临床医学院,江苏扬州,225001扬州大学医学部基础医学院·公共卫生学院,江苏扬州,225001||扬州大学医学部第一临床医学院,江苏扬州,225001扬州大学医学部第一临床医学院,江苏扬州,225001扬州大学医学部第一临床医学院,江苏扬州,225001扬州大学医学部中医药学院,江苏扬州,225001广西出生缺陷防治基础研究重点实验室/广西壮族自治区妇幼保健院,广西南宁,530002扬州大学医学部基础医学院·公共卫生学院,江苏扬州,225001||扬州大学医学部第一临床医学院,江苏扬州,225001

医药卫生

β-地中海贫血脂质体红细胞膜微小RNA纳米颗粒药物递送系统NF-E2相关因子2基因治疗

β-thalassemialiposomeserythrocyte membranemicroRNAsnanoparticlesdrug delivery systemsNF-E2 related factor 2gene therapy

《实用临床医药杂志》 2026 (15)

1-7,7

国家自然科学基金项目(22472146)广西出生缺陷防治基础研究重点实验室(广西壮族自治区妇幼保健院)开放课题支持项目(GXWCH-ZDKF-2023-16)国家级大学生创新创业训练计划项目(202511117012)

10.7619/jcmp.20261791

评论